Randomized clinical trials are a fundamental part of the process by which new medical knowledge is acquired and translated into clinical practice. Patients volunteer to participate in clinical trials in good faith that the results will be made available as quickly and as openly as possible to the medical community and that their participation will contribute to improved health for others. Unfortunately, in practice this does not always happen. One of the major reasons is failure to publish the complete data set, in particular when the trial has produced results suggesting that the treatment under investigation is less effective or only marginally more effective than the comparator treatment. This is particularly a problem with industry sponsored studies. The problem is compounded by researchers and journal editors usually being more interested in publishing trial outcomes that either show a large effect for a new treatment (positive trials) or equivalence of two methods of treatment (non-inferiority trials). Journal editors and researchers are less keen to publish results that show that a new treatment was inferior to standard treatment (negative trials) and even less keen to publish the results of trials that are inconclusive since these trials will not change clinical practice.
The benefits of trial registration are substantial: reduction of the potential for patient harm, reduction in the duplication of trials, better planning of further studies and the reduction in negative reporting bias. Evidence-based medicine requires easy access to trial data especially when this is negative, otherwise the results of meta-analysis will overestimate any positive effects. If all clinical trials were registered in public registers at their inception as part of the public record, then all stakeholders in clinical research would be able to benefit by being able to explore the full range of clinical evidence.
In [3] .
The World Health Organization (WHO) has developed a single worldwide standard for the information that trial authors must disclose (Table 1 ). It is important that the requested information is registered for each trial. Trial registration with missing or uninformative fields for the minimum data elements listed in Table 1 The unique trial number will be established be the primary registering entity (the registry).
Trial registration date
The date of registration will be established by the primary registering entity.
Secondary IDs
May be assigned by sponsors or other interested parties (there may be none).
Funding source(s)
Name of the organization(s) that provided funding for the study.
Primary sponsor
The main entity responsible for performing the research. 6. Secondary sponsor(s)
The secondary entities, if any, responsible for performing the research.
Responsible contact person
Public contact person for the trial, for patients interested in participating.
Research contact person
Person to contact for scientific inquiries about the trial. 9. Title of the study Brief title chosen by the research group (can be omitted if the researchers wish). 10. Official scientific title of the study This title must include the name of the intervention, the condition being studied and the outcome (e.g. The International Study of Digoxin and Death from Congestive Heart Failure).
Research ethics review
Has the study at the time of registration received appropriate ethics committee approval (yes/no)? (It is assumed that all registered trials will be approved by an ethics board before commencing.) 12. Condition
The medical condition being studied (e.g. asthma, myocardial infarction and depression).
Intervention(s)
A description of the study and comparison/control intervention(s) (For a drug or other product registered for public sale anywhere in the world, this is the generic name; for an unregistered drug the generic name or company serial number is acceptable). The duration of the intervention(s) must be specified. 14. Key inclusion and exclusion criteria Key patient characteristics that determine eligibility for participation in the study.
Study type
Database should provide drop-down lists for selection. This would include choices for randomized vs non-randomized, type of masking (e.g. double blind, single blind), type of controls (e.g. placebo and active) and group assignment, (e.g. parallel, crossover and factorial).
Anticipated trial start date
Estimated enrolment date of the first participant.
Target sample size
The total number of subjects the investigators plan to enrol before closing the trial to new participants.
Recruitment status Is this information available (yes/no) (If yes, link to information). 19. Primary outcome
The primary outcome that the study was designed to evaluate. Description should include the time at which the outcome is measured (e.g. blood pressure at 12 months). 20. Key secondary outcomes
The secondary outcomes specified in the protocol. Description should include time of measurement (e.g. creatinine clearance at 6 months).
NB: The data fields were specified at a meeting convened by the WHO in April 2004; the explanatory comments are largely from the ICMJE. Concerns have been raised that trial registration is just another bureaucratic hurdle for the hapless researcher to undertake before beginning a study; however, registration is quite speedy and now in many countries is a requirement for ethical committee approval.
The requirements for clinical registration and definitions of clinical trials have developed and been re-evaluated since the first registration policy was initiated by the ICMJE in 2005.
Rheumatology is adopting the WHO definition for clinical trials and the ICMJE criteria for health outcomes. For the purposes of registration, a clinical trial is 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, processof-care changes, preventative care, etc.' [5] . The ICMJE criteria for health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events [6] . Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration [6] . Those who are uncertain whether their trial meets the above definitions should err on the side of registration.
An increasing number of biomedical journals are adopting this policy, and we believe that Rheumatology should introduce a similar policy. Rheumatology will therefore require the registration of all clinical trials in line with the ICMJE and WHO declarations. We will require that from 1 January 2009 all prospective, interventional studies whether begun before or after that date must be registered with either with a WHO Primary Registry or an approved ICMJE registry. Trials beginning after 1 January 2009 must be registered before recruitment of the first patient. Rheumatology will accept 'retrospective registration' of trials that began before 1 January 2009 (retrospective meaning registration occurs after patient enrolment begins). When submitting a paper on a clinical trial, the trial registration number should be stated at the end of the abstract in the following format: Trial registration: [name of the trial registry, the registry URL and the trial registration number]. We hope that this policy will encourage the more open and honest reporting of the results from clinical trials benefiting the medical community. 
